New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTBAYRY, ONXXBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
13:37 EDTBAYRYPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
October 20, 2014
07:11 EDTBAYRYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 14, 2014
14:03 EDTBAYRYCompugen achieves second preclinical milestone under Bayer cancer collaboration
Compugen (CGEN) disclosed that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced relates to the second preclinical milestone for one of the checkpoint protein candidates.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use